Strategy Update: Switch 2% of Neuren Pharma (NEU) to Telix Phama(TLX)
Switching from Neuren Pharma (NEU) to Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.
Switching from Neuren Pharma (NEU) to Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.